Expansion for new sales force

Quote












Lee Weinstein, acting chief of the metabolic diseases branch of National Institute of Diabetes and Digestive and Kidney Diseases in the National Institutes of Health (NIH), voted for approval.

"I would honestly say I was very much on the fence with this, and perhaps at another time or another moment, I could have made my vote the other way," he said, adding that he "was not overly impressed with the study that was done and some of the outcomes that were shown in the data. To be honest with you, as a physician, I think I would probably very rarely if ever even prescribe it." Still, he said, there appear to be a "insignificantly small number of very difficult-to-treat patients that, for whatever reason – and I'm not sure we totally understand why that is" – are helped by the drug.
 






Anonymous said:
Lee Weinstein, acting chief of the metabolic diseases branch of National Institute of Diabetes and Digestive and Kidney Diseases in the National Institutes of Health (NIH), voted for approval.

"I would honestly say I was very much on the fence with this, and perhaps at another time or another moment, I could have made my vote the other way," he said, adding that he "was not overly impressed with the study that was done and some of the outcomes that were shown in the data. To be honest with you, as a physician, I think I would probably very rarely if ever even prescribe it." Still, he said, there appear to be a "insignificantly small number of very difficult-to-treat patients that, for whatever reason – and I'm not sure we totally understand why that is" – are helped by the drug.
Click to expand...

THANK YOU for posting this! I have heard the same from the endocrinologists that I call on! The FDA states lack of efficacy, lack of a series need to approve this prematurely, and lack of impressive outcomes in the data presented. While for those 'insignificantly small number of difficult to treat" patients this could have a place and be approved, it needs additional studies, specific dosing that demonstrates efficacy and from a business perspective, Natpara shouldn't be launched with a sales force of 50. Absolutely unethical for those who sign on only to be let go in a year.
 






Anonymous said:
THANK YOU for posting this! I have heard the same from the endocrinologists that I call on! The FDA states lack of efficacy, lack of a series need to approve this prematurely, and lack of impressive outcomes in the data presented. While for those 'insignificantly small number of difficult to treat" patients this could have a place and be approved, it needs additional studies, specific dosing that demonstrates efficacy and from a business perspective, Natpara shouldn't be launched with a sales force of 50. Absolutely unethical for those who sign on only to be let go in a year.
Click to expand...

You're obviously speaking with different endocrinologists than me.

The folks with whom I've spoken are excited about having Natpara available to them.

Dr. Weinstein is not an endcrinologist and likely hasn't seen a patient in a long time, if ever.

Seek out an endocrinologist with a clinical interest in thyroid disease and you'll hear a much different opinion than Dr. Weinstein's.
 












The endo I asked said to read this paper

J Pediatr Endocrinol Metab. 2014 Jan 1;27(1-2):53-9. doi: 10.1515/jpem-2013-0159.
Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.
Matarazzo P, Tuli G, Fiore L, Mussa A, Feyles F, Peiretti V, Lala R.
Abstract
Abstract Background: Subcutaneous recombinant human parathormone [rhPTH (1-34)] has been introduced for hypoparathyroidism treatment,

He claims everybody uses Forteo
 






Anonymous said:
The endo I asked said to read this paper

J Pediatr Endocrinol Metab. 2014 Jan 1;27(1-2):53-9. doi: 10.1515/jpem-2013-0159.
Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.
Matarazzo P, Tuli G, Fiore L, Mussa A, Feyles F, Peiretti V, Lala R.
Abstract
Abstract Background: Subcutaneous recombinant human parathormone [rhPTH (1-34)] has been introduced for hypoparathyroidism treatment,

He claims everybody uses Forteo
Click to expand...

For peds patients, he may be right. Natpara was studied in adults aged 18-85.
 


















Anonymous said:
when will we be getting offers ? I'm worried because my PIP ends in December surely will we have the final offers this month ??
Click to expand...

If you're on a PIP, you're not getting an offer.

And if you happen to come onboard under dishonest circumstances, you'll be let go once your RBD finds out.

I've seen it happen.
 






















































Quit lying - obviously you were never hired. We are rolling in cash, my wife likes to cash our bonus check and throw the money on the bed. Then we jump on the bed while the cash flies everywhere. Gattex is a total blockbuster - sales ?? there's no sales !! They are begging please please let me have some. Biggest problem is the length of the lines at the pharmacy of people waiting to fill their prescriptions.
 






Top Bottom
Back
Quote